Phase II Single Arm study of AZD9291 to treat NSCLC patients in Asia Pacific

Trial Identifier: D5160C00017
Sponsor: AstraZeneca
Start Date: June 2015
Primary Completion Date: March 2016
Study Completion Date: December 2025
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Kogarah, AU, 2217
AU Nedlands, AU, 6009
AU Woolloongabba, AU, 4102
CN Beijing, CN, 100142
CN Beijing, CN, 100021
CN Beijing, CN, 100730
CN Changchun, CN, 130000
CN Chengdu, CN, 610041
CN Chongqing, CN, 400038
CN Chongqing, CN, 400042
CN Fuzhou, CN, 350014
CN Haikou, CN, 570311
CN hangzhou, CN, 310006
CN Hangzhou, CN, 310022
CN Hangzhou, CN, 310003
CN Harbin, CN, 150049
CN Jinan, CN, 250117
CN Nanjing, CN, 210009
CN Shanghai, CN, 200032
CN Shanghai, CN, 200030
CN Shanghai, CN, CN-200433
CN Wuhan, CN, 430022
CN Wuhan, CN, 430030
CN xi'an, CN, 710038
CN Xi'an, CN, 710032
CN Zhengzhou, CN, 450008
KR Goyang-si, KR, 10408
KR Seongnam-si, KR, 13620
KR Seoul, KR, 6351
KR Seoul, KR, 05505